Mass Tort brief
Redesigning Corporate Liability
The High Court establishes a staged trial format for major talc litigation while narrowing emissions claims in the historic diesel emissions class actions.
Mass Tort
The High Court's landmark ruling severely curtails the UK's massive dieselgate litigation — establishing a clear legal divergence between British and European emissions liability standards.
BackgroundThe Pan-NOx Emissions litigation represents the largest group action in English legal history, targeting emissions cheating. Vehicle owners claimed that car manufacturers installed illegal software to manipulate emissions-control systems during laboratory testing.
- Lady Justice Cockerill dismissed all defeat-device claims against Ford, Renault, and Nissan, finding their engine-protection strategies lawful and justifiable.
- The judge made limited adverse findings only against Mercedes-Benz and Peugeot-Citroën, scheduling a damages trial for October to determine compensation.
- In a controversial move, the court declined to follow post-Brexit European Court of Justice precedents on emissions regulations, underscoring British judicial independence.
Mass Tort
The High Court's staged trial design forces UK talc litigation to resolve the core scientific questions first — isolating the legal battle from US settlement dynamics.
BackgroundThousands of UK claimants allege that Johnson & Johnson's mineral talc-based baby powder was contaminated with asbestos, causing mesothelioma or ovarian cancer. In the US, the healthcare giant has proposed a $5.5 billion settlement to resolve similar claims under bankruptcy protection.
- Mrs Justice Hill ordered that the initial trial focus on whether J&J's talc was contaminated and capable of causing the alleged cancers, postponing arguments over individual damages.
- The judge rejected claimants' attempts to probe J&J's historical knowledge of the asbestos risks during this initial scientific stage, keeping the immediate focus strictly on biochemistry.
- Lead solicitor Tom Longstaff confirmed that J&J's US settlement offers will have no effect on the UK litigation, forcing a separate resolution process for British victims.
- The court set a hard deadline of January 18, 2027, for new claimants to join the Group Litigation Order register, capping the ultimate size of the class.
Mass Tort
The appeals court's ruling solidifies AstraZeneca's statutory immunity — demonstrating that the PREP Act shields pharma giants even from voluntary trial contract obligations.
BackgroundThe US PREP Act was enacted to shield pharmaceutical manufacturers from liability during public health emergencies. Whether this statutory immunity extended to voluntary informed-consent contracts signed during clinical trials remained a key legal loophole.
- The lawsuit was brought by Brianne Dressen, who suffered severe post-vaccine neuropathy during a 2020 AstraZeneca clinical trial, drawing national attention to trial participant safety.
- The plaintiff alleged that AstraZeneca breached its agreement by failing to pay for medical care after she was injured, setting up a clash over private contract rights.
- The appeals court remanded the case for a narrow determination on whether AstraZeneca explicitly waived its statutory immunity, leaving a thin legal opening for the plaintiff.
Mass Tort
The appeals court's ruling raises the bar for pharmaceutical fraud class actions — forcing plaintiffs to prove a direct, causal link to doctor decisions.
BackgroundThe 19-year-old multidistrict litigation accuses GSK of fraudulently misrepresenting the cardiovascular risks of its diabetes drug Avandia. Third-party health plans claimed this deception caused them to cover higher-cost prescriptions instead of safer alternatives.
- GSK highlighted the vacatur in its Q2 2026 earnings report, noting it significantly reduces its potential litigation exposure after decades of defending the claims.
- The Third Circuit ruled that plaintiffs must present causation-grade statistical proof linking marketing to physician prescribing habits, raising the evidentiary standard for health plans.
- The court declared that mere correlation between marketing statements and overall prescribing trends was insufficient to certify a class, dealing a blow to indirect purchaser actions.
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.